Since impaired mucus production and obesity-driven intestinal inflammation are the likely mechanisms increasing permeability of the mucosal barrier and systemic endotoxin levels33, 34 (Fig. 2), we hypothesised that in obese mice treated with IL-22, reduced ER stress and inflammation would lead to improved intestinal barrier function. Here, IL22 is linked to obesity disorder.